Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy
Clinical Cancer Research2013Vol. 19(24), pp. 6730–6740
Citations Over TimeTop 10% of 2013 papers
Yvonne Kienast, Christian Klein, Werner Scheuer, Romi Raemsch, Erica Lorenzon, Dirk Bernicke, Frank Herting, Sidney Yu, Huynh Hung The, Laurent Martarello, Christian Gassner, Kay-Gunnar Stubenrauch, Kate Munro, Hellmut G. Augustin, Markus Thomas
Abstract
These data establish Ang-2-VEGF-A CrossMab as a promising antitumor, antiangiogenic, and antimetastatic agent for the treatment of cancer.
Related Papers
- → Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: Therapeutic implications(2002)625 cited
- → Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: Therapeutic implications(2002)547 cited
- Testing the Effect of Bevacizumab Treatment on VEGF Signaling in Vitro(2015)
- Progress in Anti-tumor Angiogenesis Drugs Targeting VEGF/VEGFR(2014)
- → P2.01-008 Combination of Bavacizumab with Conventional Chemotherapy Shows Better Prognosis in Patients with Lung Cancer with Liver Metastasis(2017)